Format

Send to

Choose Destination
J Assist Reprod Genet. 2010 Aug;27(8):495-9. doi: 10.1007/s10815-010-9434-3. Epub 2010 May 18.

Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors.

Author information

1
NYU Fertility Center, NYU School of Medicine, New York, NY 10016, USA. nnoyes01@gmail.com

Abstract

PURPOSE:

To compare oocyte cryopreservation cycles performed in cancer patients to those of infertile women.

METHODS:

Cancer patients referred for fertility preservation underwent counseling in compliance with the ASRM; those electing oocyte cryopreservation were included. Ovarian stimulation was achieved with injectable gonadotropins and freezing was performed using slow-cooling and vitrification methods.

RESULTS:

Fifty cancer patients (mean age 31 y) underwent oocyte cryopreservation; adequate ovarian stimulation was achieved in 10 ± 0.3 days. The outcome from these cycles included a mean peak estradiol of 2,376 pg/ml and an average of 19 oocytes retrieved (15 mature oocytes were cryopreserved/cycle). All patients tolerated ovarian hyperstimulation. There were no significant differences noted between cryopreservation cycles performed in cancer patients and in women without malignancy.

CONCLUSIONS:

Oocyte cryopreservation appears to be a feasible fertility preservation method for reproductive-age women diagnosed with cancer. This modality is not only effective but also, providing a multidiscipline effort, can be completed in timely fashion.

PMID:
20480389
PMCID:
PMC2941585
DOI:
10.1007/s10815-010-9434-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center